Betta L (300558.SZ) traded flat 0 % during a 24 hours period ending at 05:30 AM Central Europe on Tuesday 27th. One Betta L stock can currently be bought for about CNY 40.95 on popular exchanges. Current supply of Betta L stocks is 420.8 mn. Betta L has a current market capitalization of CNY 17.9 bn and approximately CNY 452.1 mn worth of Betta L was traded on exchanges in the last 24 hours. Since last month end, Betta L has traded -11.61 % down. Simple moving average of last 200 days is at CNY 54.49. The highest price of past 52 weeks was recorded at CNY 78.18 on 07/06/2026. 52 weeks low was at CNY 38.2 on 10/20/2026.
Here is how related stocks have performed in the past 24 hours:
Hubei Sinophorus Electroni (688545.SS) traded flat 0 % and now trades at CNY 60.22. Hubei Sinophorus Electroni has a market capitalisation of CNY 21.5 bn. Hubei Sinophorus Electroni has a current price to earnings ratio of 93.06.
Luxi Chemical Lt (000830.SZ) traded flat 0 % and now trades at CNY 11.28. Current market capitalisation for Luxi Chemical Lt is CNY 21.4 bn. Current price/earnings ratio for Luxi Chemical Lt is 19.13.
Jiangsu Yangnong Chemical (600486.SS) traded flat 0 % and now trades at CNY 53.65. Jiangsu Yangnong Chemical has a market capitalisation of CNY 21.4 bn. Current price/earnings ratio for Jiangsu Yangnong Chemical is 16.87.
Beibuwan Port (000582.SZ) traded flat 0 % and now trades at CNY 8.38. Beibuwan Port has a market capitalisation of CNY 21.4 bn. Beibuwan Port has a current price to earnings ratio of 19.67.
Dongguan Dingtong Precisio (688668.SS) traded flat 0 % and now trades at CNY 140.78. Current market capitalisation for Dongguan Dingtong Precisio is CNY 21.4 bn. Current price/earnings ratio for Dongguan Dingtong Precisio is 115.44.
About Betta L
Bet Pharmaceuticals Co.,Ltd is a health care company operating in the pharmaceutical industry, specializing in the research and development, manufacturing, sale, and marketing of drugs for the treatment of malignant tumors, diabetes, cardiovascular, and cerebrovascular diseases in China. The company offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. It has strategic partnership with Amgen Inc. for the commercialization of Vectibix in the Chinese market; and a collaboration agreement with InventisBio Inc. Bet Pharmaceuticals was founded in 2003 and has its headquarters in Hangzhou, China. The company’s website is accessible under www.bettapharma.com , and it is listed on the Shenzhen Stock Exchange.
